Business Context and Reporting Period
This Form 6-K filing by Scinai Immunotherapeutics Ltd. covers the month of May 2026. The report discloses the completion of the acquisition of Recipharm Israel Ltd. (renamed Scinai Biopharma Services Ltd.) on February 17, 2026. The filing furnishes audited financial statements of the subsidiary as of December 31, 2025, and unaudited pro forma condensed consolidated financial information reflecting the acquisition.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references the existence of audited financial statements for the subsidiary and pro forma combined information as Exhibits 99.1 and 99.2, but the actual figures are not included in the provided text.
Material Changes
The primary material change is the acquisition of Scinai Biopharma Services Ltd., which expands the Company's operations into Contract Development and Manufacturing Organization (CDMO) services. The pro forma financial information presents the Company's financial position as if this acquisition had occurred on the dates indicated, though the text notes this is not necessarily indicative of future results.
Guidance, Outlook, and Risks
Management commentary indicates a business strategy focused on developing and growing the CDMO business while advancing therapeutic development programs. The filing includes forward-looking statements subject to significant risks and uncertainties, including:
- The ability to successfully integrate and operate the subsidiary's operations.
- The success of the business strategy and CDMO growth.
- The final determination of fair values for assets acquired and liabilities assumed.
- The completion of the purchase price allocation.
The Company explicitly states it undertakes no obligation to update forward-looking statements except as required by law.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific audited financial results of Scinai Biopharma Services Ltd. as of December 31, 2025.
- Analyze Exhibit 99.2 for the unaudited pro forma financial data to understand the combined entity's projected financial position.
- Verify the final purchase price allocation and fair value determinations once completed.
- Monitor the integration progress of the subsidiary's CDMO operations with the parent company's therapeutic programs.